Clinical Trial Update: A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 long-term extension trial of Risankizumab (BI 655066/ABBV-066) in moderately to severely active Crohn's disease completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Crohn Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-04-24